Study to Evaluate the Safety and Efficacy of IM19 CAR-T Cells in Patients With Relapsed and Refractory (R/R) Mantle Cell Lymphoma
Clinical trial NCT05155215 · UNKNOWN
Trial details
- NCT number
- NCT05155215
- Sponsor
- Beijing Immunochina Medical Science & Technology Co., Ltd.
- Status
- UNKNOWN
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2021-12-31
- Primary completion
- 2022-12-31
- Enrollment
- 68
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.